Kalaris Therapeutics (KLRS) vs Pelthos Therapeutics (PTHS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Pelthos Therapeutics (PTHS) has outperformed Kalaris Therapeutics (KLRS) over the past year, losing 74.9% versus a loss of 81.7%. Kalaris Therapeutics is the larger company by market cap ($30.5 million vs $25.1 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KLRS | PTHS |
|---|---|---|
| Share price | $1.28 | $6.38 |
| Market cap | $30.47M | $25.08M |
| 1-day change | -5.19% | -8.73% |
| YTD return | -84.83% | -79.42% |
| 1-year return | -81.74% | -74.88% |
| 5-year return | -99.70% | — |
| EPS (TTM) | $-1.84 | $-23.86 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $16.80M |
| Net income (latest FY) | $-43.44M | $-43.32M |
| Gross margin | — | 76.25% |
| Operating margin | — | -193.09% |
| Net margin | — | -257.93% |
| 52-week high | $11.88 | $31.62 |
| 52-week low | $1.25 | $6.02 |
| Distance from 52-week high | -89.23% | -79.82% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +1361.72% | +732.92% |
| Average volume | 77.37K | 54.38K |
| Shares outstanding | 23.80M | 3.93M |
| Employees | 20 | 92 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Kalaris Therapeutics
KLRS stock →Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 20 employees
About Pelthos Therapeutics
PTHS stock →Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestation in patients 6 months of age and older.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 92 employees
KLRS vs PTHS FAQ
Which is bigger, Kalaris Therapeutics or Pelthos Therapeutics?
Kalaris Therapeutics (KLRS) is larger, with a market capitalization of $30.47M compared with $25.08M for Pelthos Therapeutics (PTHS).
Which stock has performed better over the past year, KLRS or PTHS?
PTHS returned -74.88% over the past 12 months, compared with -81.74% for KLRS (price return, excluding dividends). Past performance does not predict future results.
Are Kalaris Therapeutics and Pelthos Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.